Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty

Longeveron Inc. LGVN announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll 45 patients and its primary objective is to evaluate safety. 

“We are excited to announce the dosing of the first patient in our Japanese Aging-Related Frailty trial,” said Wa’el Hashad, Longeveron’s Chief Executive Officer. “In 2022, Longeveron aligned with the Japan Pharmaceuticals and Medical Devices Agency (PMDA), on the Phase 2 trial design and we hope the data from this trial will provide support for a limited approval under Japan’s Act on the Safety of Regenerative Medicine (ASRM), which allows regenerative medicine products to be administered to patients by approved hospitals or clinics under the practice of medicine. This is the first use of our U.S.-manufactured product in Japan, and we look forward to advancing Lomecel-B™ as a treatment for Aging-Related Frailty in Japan.”

Hidenori Arai, M.D., Ph.D., President of the National Center for Geriatrics and Gerontology, and principal investigator of the Phase 2 trial, commented, “I am pleased to see this clinical trial program advancing, especially given the large unmet need in Japan, where nearly 30% of the population is over the age of 65. I was encouraged by Longeveron’s previously announced Phase 2b Aging-Related Frailty study in the United States, where subjects receiving a single infusion of Lomecel-BTM showed a statistically significant and clinically meaningful improvement in walking distance at 9 months post-infusion compared to placebo. I look forward to building on that data in the Japanese population.”

The Phase 2 clinical trial is a 3-arm, parallel design, randomized (1:1:1), placebo-controlled, double-blind single infusion study of two different dose levels of Lomecel-BTM. The trial is expected to enroll 45 patients and has a primary objective of evaluating safety of Lomecel-BTM as a treatment for Aging-Related Frailty. The trial is being conducted in partnership with the National Center for Geriatrics & Gerontology (NCGG;Nagoya) and Juntendo University Hospital (Tokyo). 

Japan is considered to be a “super-aged” society with some 36.4 million individuals aged 65 or older in 2021, representing 29.1% of the population. The overall prevalence of aging-related frailty amongst this demographic is estimated to be 7.9%. 

Image sourced form Shutterstock

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&APenny StocksGeneralLongeveron
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!